A randomised double-blind controlled phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject®) with placebo in patients with chronic heart failure and iron deficiency. - FAIR-HF (Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure)

Vifor (International) Inc0 个研究点目标入组 576 人开始时间: 2007年6月11日最近更新: 2022年1月24日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Vifor (International) Inc
入组人数: 576

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. At least 18 years of age and signed written informed consent.
•2. In NYHA II-III functional class due to stable symptomatic CHF, and all of the following:
•a. Two weeks without cardiac hospitalisation.
•b. Patients in NYHA II must have had an unplanned hospital admission or emergency room visit for worsening of heart failure within 12 months prior to randomisation.
•c. On optimal conventional therapy (in general, optimal pharmacological treatment which includes a diuretic, a beta-blocker, and/or an angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) as determined by the investigator, unless contraindicated or not tolerated).
•d. No dose changes of heart failure drugs during the last 2 weeks (with the exception of diuretics).
•e. No introduction of a new heart failure drug class during the last 4 weeks.
•3. Left ventricular ejection fraction (LVEF) 35% or lower as assessed according to local methodology by 2-D echocardiography, radionuclide ventriculography, cardiac magnetic resonance imaging, or X-ray contrast ventriculography within 6 months prior to randomisation. For patients treated with beta-blockers or with cardiac resynchronisation, LVEF assessment for eligibility must be performed at least 3 months after stable beta-blocker therapy or device implantation.
•4. Estimated glomerular filtration rate (e-GFR) below 60 mL/min/1.73m2 as calculated using the Modification of Diet in Renal Disease trial (MDRD) formula.
•5. Screening Hb at least 9.5 g/dL but below or equal to 13.5 g/dL (average of 2 haemoglobin concentrations as measured locally by HemoCue® analyzer; see Section 3.3.5.2 of protocol).
•6. Screening ferritin below 100 µg/L, or below 300 µg/L when transferrin saturation (TSAT) is below 20%.
•7. Resting blood pressures less than or equal to 160 mm Hg (systolic) and less than or equal to 100 mm Hg (diastolic at the disappearance of sounds, Korotkoff phase V).
•8. Adequate veins for repeated blood sampling and i.v. administration of investigational drug.
•9. Negative pregnancy test and use of adequate contraceptive methods for women of childbearing potential.
•10. Patient must be able to perform the 6 minute walk test according to investigator judgement
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1. History of acquired iron overload.
•2. Known hypersensitivity to Ferinject®.
•3. Known active infection, CRP > 20 mg/L, clinically significant bleeding, active malignancy.
•4. Chronic liver disease and/or screening alanine transaminase (ALT) or aspartate transaminase (AST) above three times the upper limit of the normal range.
•5. Anaemia due to reasons other than iron deficiency (e.g. haemoglobinopathy).
•6. Immunosuppressive therapy or renal dialysis (current or planned within the next 6 months).
•7. History of erythropoietin, i.v. or oral iron therapy, and blood transfusion in previous 12 weeks and/or such therapy planned within the next 6 months.
•8. Unstable angina pectoris as judged by the investigator, clinically significant uncorrected valvular disease or left ventricular outflow obstruction, obstructive cardiomyopathy, poorly controlled fast atrial fibrillation or flutter, poorly controlled symptomatic brady- or tachyarrhythmias.
•9. Acute myocardial infarction or acute coronary syndrome, transient ischaemic attack or stroke within the last 3 months.
•10. Coronary-artery bypass graft, percutaneous intervention (e.g. cardiac, cerebrovascular, aortic; diagnostic catheters are allowed) or major surgery, including thoracic and cardiac surgery, within the last 3 months.
•11. Known HIV/AIDS.
•12. Inability to fully comprehend and/or perform study procedures in the investigator’s opinion.
•13. Vitamin B12 and/or serum folate deficiency according to the central laboratory (re-screening is possible after substitution therapy).
•14. Pregnancy or lactation.
•15. Participation in another clinical trial within previous 30 days and/or anticipated participation in another trial during this study.

研究者

发起方

Vifor (International) Inc

相似试验

进行中（未招募）

不适用

A randomised double-blind controlled phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject®) with placebo in patients with chronic heart failure and iron deficiency. - FAIR-HF (Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure)iron deficiency in patients with chronic heart failureMedDRA version: 8.1Level: PTClassification code 10022970Term: Iron deficiency

EUCTR2006-004608-37-BEVifor (International) Inc576

进行中（未招募）

1 期

EUCTR2006-004608-37-GRVifor (International) Inc576

进行中（未招募）

不适用

EUCTR2006-004608-37-DEVifor Pharma, Vifor (International) Ltd.576

进行中（未招募）

1 期

PREVENTT (Preoperative intravenous iron to treat anaemia in major surgery)AnaemiaMedDRA version: 19.0Level: PTClassification code 10022972Term: Iron deficiency anaemiaSystem Organ Class: 10005329 - Blood and lymphatic system disorders

EUCTR2012-002786-35-GBniversity College London500

进行中（未招募）

不适用

A randomised double-blind controlled phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject) with placebo in patients with chronic heart failure and iron deficiency - FAIR-HF

EUCTR2006-004608-37-ITVIFOR (INTERNATIONAL) INC.576